Medicare ‘coverage with evidence development’ for Aducanumab? How might it work?

Date: June 30, 2021
Journal: Health Affairs Blog
Citation: Chambers J, Lin P, Tunis SR, Neumann PJ, Medicare ‘Coverage With Evidence Development’ For Aducanumab? How Might It Work? Health Affairs, June 30, 2021.

In the wake of the Food and Drug Administration’s (FDA’s) controversial decision to approve aducanumab for Alzheimer’s disease, how will, and how should, Medicare respond? We propose a coverage with evidence development (CED) option for the Centers for Medicare and Medicaid Services (CMS), and we examine how the agency’s past decisions on high-price technology may offer a guide. While others have written generally about Medicare’s options for aducanumab, including possible action from CMS’s Center for Medicare and Medicaid Innovation, we elaborate on the design of CED studies, drawing on lessons from historical CMS decisions

More Publications